Headlands Technologies LLC Sells 1,245 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Headlands Technologies LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 62.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 736 shares of the biotechnology company’s stock after selling 1,245 shares during the period. Headlands Technologies LLC’s holdings in United Therapeutics were worth $162,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in UTHR. Asset Management One Co. Ltd. increased its position in shares of United Therapeutics by 2.8% during the third quarter. Asset Management One Co. Ltd. now owns 22,968 shares of the biotechnology company’s stock valued at $5,188,000 after purchasing an additional 633 shares during the period. Handelsbanken Fonder AB raised its stake in shares of United Therapeutics by 8.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 7,900 shares of the biotechnology company’s stock valued at $1,784,000 after buying an additional 600 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of United Therapeutics by 9.0% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 1,705 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 141 shares during the period. Robeco Institutional Asset Management B.V. lifted its holdings in shares of United Therapeutics by 125.2% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 87,048 shares of the biotechnology company’s stock worth $19,662,000 after acquiring an additional 48,397 shares during the period. Finally, Raymond James & Associates boosted its position in shares of United Therapeutics by 1.7% during the 3rd quarter. Raymond James & Associates now owns 28,054 shares of the biotechnology company’s stock valued at $6,337,000 after acquiring an additional 471 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.9 %

Shares of UTHR opened at $233.85 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. The company has a market cap of $11.00 billion, a price-to-earnings ratio of 11.79 and a beta of 0.52. The stock has a fifty day moving average price of $233.74 and a two-hundred day moving average price of $228.76. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $261.54.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.67 earnings per share. Analysts predict that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $215.01, for a total value of $1,290,060.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,869,150.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,869,150.99. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total transaction of $77,285.00. Following the completion of the transaction, the director now directly owns 5,373 shares in the company, valued at $1,277,699.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 136,990 shares of company stock worth $32,239,641. Corporate insiders own 12.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on UTHR shares. HC Wainwright restated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and raised their target price for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. SVB Leerink started coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.